| Size | Price | |
|---|---|---|
| 250mg | ||
| Other Sizes |
| Targets |
HDAOS does not have a specific biological target in the traditional sense of receptor or enzyme inhibition. Instead, it functions as a chromogenic substrate that participates in oxidative coupling reactions catalyzed by peroxidase in the presence of hydrogen peroxide. The compound reacts with 4-aminoantipyrine (4-AA) or 3-methylbenzothiazolone hydrazone (MBTH) to form stable colored complexes. Its primary "target" in diagnostic applications is the hydrogen peroxide generated by enzymatic reactions involving analytes such as glucose, cholesterol, and uric acid. HDAOS serves as a water-soluble reagent for the determination of hydrogen peroxide by enzyme spectrophotometry.
|
|---|---|
| ln Vitro |
HDAOS exhibits excellent in vitro chromogenic activity as a Trinder's reagent. In the presence of peroxidase and hydrogen peroxide, HDAOS undergoes oxidative coupling with 4-aminoantipyrine to form a highly stable purple or blue dye. The resulting colored complex exhibits strong absorbance, enabling sensitive and accurate quantification of hydrogen peroxide and, by extension, various analytes that generate hydrogen peroxide through enzymatic reactions. HDAOS offers advantages over conventional chromogenic reagents in colorimetric determination of hydrogen peroxide activity, including superior water solubility, enhanced stability, and high sensitivity. The compound's high purity (≥98%) and good water solubility ensure consistent and reliable assay performance.
|
| ln Vivo |
In vivo activity data for HDAOS are not applicable, as this compound is a diagnostic reagent used exclusively for in vitro biochemical assays and clinical diagnostic testing. HDAOS is not intended for therapeutic use or administration to living organisms. Its function is limited to serving as a chromogenic substrate in colorimetric assays for detecting specific analytes in biological samples such as serum, plasma, or urine. The compound's utility lies in its ability to facilitate the quantification of clinically relevant analytes including glucose, cholesterol, uric acid, and triglycerides in diagnostic laboratory settings. No in vivo pharmacological or toxicological studies have been reported for this reagent.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for HDAOS involves a colorimetric detection system based on the Trinder's reaction. The assay protocol typically includes the following steps: prepare a reaction mixture containing the sample (e.g., serum or plasma), the target enzyme (such as glucose oxidase or cholesterol oxidase), HDAOS, and 4-aminoantipyrine in an appropriate buffer system. Incubate the mixture at 37degC for a specified period to allow enzymatic generation of hydrogen peroxide. In the presence of peroxidase, HDAOS reacts with hydrogen peroxide and 4-aminoantipyrine to form a purple or blue dye. Measure the absorbance of the colored product at a specific wavelength (typically around 550-600 nm) using a spectrophotometer or microplate reader. The absorbance is proportional to the concentration of the analyte being measured, enabling quantitative determination.
|
| Cell Assay |
The in vitro cell-based assay for HDAOS is not typically performed, as HDAOS is a chromogenic reagent used in biochemical and diagnostic assays rather than a compound tested on cultured cells. However, in the context of assay development, HDAOS can be used in cell culture supernatants or cell lysates to measure the production of hydrogen peroxide or the activity of enzymes that generate hydrogen peroxide. The general procedure involves collecting cell culture samples, adding them to a reaction mixture containing HDAOS, 4-aminoantipyrine, and peroxidase, and incubating at 37degC. The formation of the colored complex is then measured spectrophotometrically. This approach can be used to assess oxidative stress, metabolic activity, or enzyme function in cell-based systems.
|
| Animal Protocol |
In vivo animal studies are not applicable for HDAOS, as this compound is a diagnostic chromogenic reagent used exclusively for in vitro biochemical assays and clinical diagnostic testing. HDAOS is not intended for therapeutic applications or administration to animals in pharmacological studies. The compound is designed to function as a chromogenic substrate in colorimetric assays for detecting specific analytes in biological samples, and its utility is limited to laboratory diagnostics and biochemical research. No animal studies involving the administration of HDAOS have been reported, and such studies would not be relevant given the compound's intended use as a diagnostic reagent rather than a therapeutic agent.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable for HDAOS, as this compound is a diagnostic chromogenic reagent used exclusively for in vitro biochemical assays and is not administered to living organisms. The compound has a molecular weight of 313.30 g/mol and a molecular formula of C11H1₆NO₆SNa. HDAOS is characterized by high water solubility, with solubility in water and a purity of ≥98%. The compound is stored at -20degC for long-term stability and appears as a white or off-white powder. Its physicochemical properties include a LogP of 1.17560, a topological polar surface area of 116, and 7 hydrogen bond acceptors and 2 hydrogen bond donors.
|
| Toxicity/Toxicokinetics |
Toxicity data for HDAOS are limited, as the compound is a diagnostic reagent intended for in vitro use rather than therapeutic administration. When handled according to standard laboratory safety protocols, HDAOS is considered safe for routine use in diagnostic and biochemical applications. The compound should be handled with appropriate personal protective equipment including gloves and lab coats to prevent skin contact and inhalation of dust. Standard safety data sheet (SDS) precautions should be followed, including avoiding ingestion, inhalation, and contact with eyes and skin. In case of accidental exposure, rinse affected areas with plenty of water and seek medical attention if irritation persists. Proper disposal procedures for chemical waste should be observed in accordance with local regulations.
|
| Additional Infomation |
HDAOS (CAS#: 82692-88-4) is a novel Trinder's reagent also known as N-(2-Hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline sodium salt. It belongs to the family of highly water-soluble aniline derivatives and is widely used in diagnostic detection and biochemical testing. During oxidative coupling reactions with 4-aminoantipyrine or 3-methylbenzothiazolone hydrazone in the presence of peroxidase and hydrogen peroxide, HDAOS forms very stable purple or blue dyes. The compound offers several advantages over conventional chromogenic reagents, including high sensitivity, excellent stability, and superior water solubility. HDAOS is commonly employed in enzymatic assays for the determination of glucose, cholesterol, uric acid, triglycerides, and other clinically relevant analytes. It is available with high purity (≥98%) and is intended for research and diagnostic use only, not for human therapeutic applications.
|
| Molecular Formula |
C11H16NO6S-.NA+
|
|---|---|
| Molecular Weight |
313.30264
|
| Exact Mass |
313.059
|
| CAS # |
82692-88-4
|
| PubChem CID |
23666667
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.175
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
20
|
| Complexity |
348
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC(=CC(=C1)NCC(CS(=O)(=O)[O-])O)OC.[Na+]
|
| InChi Key |
SVLRFMQGKVFRTB-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C11H17NO6S.Na/c1-17-10-3-8(4-11(5-10)18-2)12-6-9(13)7-19(14,15)16;/h3-5,9,12-13H,6-7H2,1-2H3,(H,14,15,16);/q;+1/p-1
|
| Chemical Name |
sodium;3-(3,5-dimethoxyanilino)-2-hydroxypropane-1-sulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~9.8 mg/mL (~31.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1918 mL | 15.9591 mL | 31.9183 mL | |
| 5 mM | 0.6384 mL | 3.1918 mL | 6.3837 mL | |
| 10 mM | 0.3192 mL | 1.5959 mL | 3.1918 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
